Tech Center 1600 • Art Units: 1618
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19326445 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | Non-Final OA | NOVARTIS AG |
| 18628570 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | Non-Final OA | NOVARTIS AG |
| 18440783 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | Final Rejection | NOVARTIS AG |
| 19242849 | COPPER-64 COMPOSITIONS AND FORMULATIONS | Non-Final OA | Curium US LLC |
| 17622060 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USES THEREOF | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 16870484 | Compositions And Methods For Imaging Immune Cells | Final Rejection | The Trustees of the University of Pennsylvania |
| 18757905 | METAL ALKOXIDE COMPOUND, THIN FILM FORMING RAW MATERIAL, AND THIN FILM PRODUCTION METHOD | Non-Final OA | ADEKA Corporation |
| 16627872 | TREATMENTS FOR A HEMATOLOGICAL MALIGNANCY | Non-Final OA | Actinium Pharmaceuticals, Inc. |
| 17495009 | X-RAY AND MRI VISIBLE SHAPE MEMORY POLYMER BIOPSY SEALING DEVICE | Non-Final OA | Shape Memory Medical, Inc. |
| 18556646 | ENHANCEMENT OF TREATMENT WITH IMMUNOTHERAPEUTIC AGENTS | Final Rejection | ACT THERAPEUTICS LTD |
| 17979367 | NEW GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | Non-Final OA | BAYER PHARMA AKTIENGESELLSCHAFT |
| 18044665 | PREPARATIONS OF RADIUM-224 AND PROGENIES FOR USE IN RADIONUCLIDE THERAPY IN COMBINATION WITH DNA REPAIR INHIBITORS | Non-Final OA | Oncoinvent AS |
| 18044678 | SIZE CONTROLLED RADIOLABELLED PARTICLES | Non-Final OA | Oncoinvent AS |
| 18009702 | PROCEDURE FOR OBTAINING GADOTERATE MEGLUMINE FROM HIGH-PURITY TETRAXETAN (DOTA) AND ITS USE IN THE PREPARATION OF INJECTABLE GALENICAL FORMULATIONS | Non-Final OA | JUSTESA IMAGEN S.A.U. |
| 17039409 | COMPOSITIONS AND RELATED METHODS FOR BLOCKING OFF-TARGET LOCALIZATION OF MANNOSYLATED DEXTRANS AND OTHER CD206 LIGANDS | Non-Final OA | Navidea Biopharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy